World Journal of Gastrointestinal Pathophysiology

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Koizumi A, Kaji K, Nishimura N, Asada S, Matsuda T, Tanaka M, Yorioka N, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Akahane T, Yoshiji H. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease. World J Gastroenterol 2024; 30(28): 3428-3446 [PMID: 39091710 DOI: 10.3748/wjg.v30.i28.3428]
URL:	https://www.wjgnet.com/2150-5330/full/v30/i28/3428.htm

(181) (177) (0) (0) (0) (20) (6089) (25)

Number	Citing Articles
1	Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng. Novel intervention for alcohol-associated liver disease. World Journal of Gastroenterology 2024; 30(39): 4308-4312 doi: 10.3748/wjg.v30.i39.4308 Abstract(686) \| Core Tip(679) \| Full Article(HTML)(2284) \| Full Article (PDF)-787K(186) \| Full Article with Cover (PDF)-1044K(206) \| Full Article (XML)-76K(141) \| Audio-316K(33) \| Peer-Review Report-178K(136) \| Answering Reviewers-82K(134) \| Times Cited (1) \| Total Visits (3744) \| Open
2	Wei-Tong Cui, Hua-Ru Xue, Dian-Fang Wei, Xiao-Yu Feng, Kai Wang. Prospects of elafibranor in treating alcohol-associated liver diseases. World Journal of Gastroenterology 2025; 31(2): 99549 doi: 10.3748/wjg.v31.i2.99549 Abstract(548) \| Core Tip(578) \| Full Article(HTML)(2008) \| Full Article (PDF)-389K(194) \| Full Article with Cover (PDF)-640K(139) \| Full Article (XML)-102K(144) \| Audio-1553K(12) \| Peer-Review Report-208K(145) \| Answering Reviewers-107K(123) \| Times Cited (0) \| Total Visits (2485) \| Open
3	Aldona Wierzbicka-Rucińska, Ewa Konopka, Sebastian Więckowski, Wojciech Jańczyk, Anna Świąder-Leśniak, Jolanta Świderska, Joanna Trojanek, Zbigniew Kułaga, Piotr Socha, Joanna Bierła. Evaluation of Defensins as Markers of Gut Microbiota Disturbances in Children with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of Clinical Medicine 2025; 14(10) doi: 10.3390/jcm14103505
4	Xie Jiacheng, Huang Guochu, Li Minhang, Cui Yinhang, Zhang Yu, Zhang Xia, Yang Jingyun, Tang Meiwen, Luo Weisheng, Ma Xiaocong. The interventional role and mechanism of total flavonoids in lychee seeds on rats with liver fibrosis. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-10007-z
5	Jing He, Wang Zhang, Pan-pan Liu, Tian-rong Pan. An MMP12-Enriched Kupffer Cell-Associated Programme Links ATF3-Associated Immunometabolic Remodeling to Hepatic Metabolic Dysfunction and Fibrotic Communication Networks. Food and Chemical Toxicology 2026; doi: 10.1016/j.fct.2026.116412
6	Yuyi Liu, Yuchen Pang, Jingkai Xie, Hailong Li, Silu Zhang, Ruimin Wang. A composite plant extract attenuates alcohol-induced hepatic lipogenesis via AMPK-FAS signaling and gut-liver axis modulation. Food Nutrition 2026; 2(1) doi: 10.1016/j.fnutr.2026.100068
7	Hang Zhang, Xuan Dong, Lei Zhu, Fu-Shan Tang. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World Journal of Gastroenterology 2024; 30(40): 4393-4398 doi: 10.3748/wjg.v30.i40.4393 Abstract(649) \| Core Tip(741) \| Full Article(HTML)(3218) \| Full Article (PDF)-406K(203) \| Full Article with Cover (PDF)-738K(178) \| Full Article (XML)-92K(139) \| Audio-1530K(16) \| Peer-Review Report-220K(133) \| Answering Reviewers-87K(145) \| Times Cited (9) \| Total Visits (3738) \| Open
8	Helen L. Molteni, Brandi M. Golden, Emily P. Y. Yu, Eric C. Liao. A small-molecule screen identifies that elafibranor links mechanical cues and Irf6-dependent epithelial differentiation. Disease Models & Mechanisms 2026; 19(2) doi: 10.1242/dmm.052649
9	Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng. Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. World Journal of Gastroenterology 2025; 31(3): 98783 doi: 10.3748/wjg.v31.i3.98783 Abstract(704) \| Core Tip(739) \| Full Article(HTML)(2211) \| Full Article (PDF)-356K(195) \| Full Article with Cover (PDF)-776K(242) \| Full Article (XML)-46K(139) \| Audio-354K(13) \| Peer-Review Report-302K(141) \| Answering Reviewers-195K(176) \| Times Cited (4) \| Total Visits (2787) \| Open
10	Yuxuan Jiang, Cristina Llorente. Gut–liver axis molecular mechanisms in alcohol-associated liver disease. Alcohol 2026; 133 doi: 10.1016/j.alcohol.2026.04.001
11	Gurleen Kaur, Rahul Jain, Palak Grover, Zarqa Yasin, Bipneet Singh. Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis and Other Liver Diseases: Mechanisms, Clinical Evidence, and Future Directions. Livers 2026; 6(4) doi: 10.3390/livers6040077
12	Youtian Zhang, Long Ren, Yinting Tian, Xiaohu Guo, Fengxian Wei, Yawu Zhang. Signaling pathways that activate hepatic stellate cells during liver fibrosis. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1454980
13	Aenne Harberts, Bernd Schnabl. Microbiota in Alcohol-Associated Organ Damage. The American Journal of Pathology 2026; 196(1) doi: 10.1016/j.ajpath.2025.05.012
14	Luciano Pirola. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. World Journal of Gastroenterology 2025; 31(4): 99312 doi: 10.3748/wjg.v31.i4.99312 Abstract(599) \| Core Tip(577) \| Full Article(HTML)(2677) \| Full Article (PDF)-483K(212) \| Full Article with Cover (PDF)-800K(146) \| Full Article (XML)-29K(147) \| Audio-1370K(13) \| Peer-Review Report-640K(128) \| Answering Reviewers-26K(139) \| Times Cited (12) \| Total Visits (3660) \| Open
15	Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo, Zi-Li Zhang. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. World Journal of Gastroenterology 2024; 30(43): 4660-4668 doi: 10.3748/wjg.v30.i43.4660 Abstract(661) \| Core Tip(661) \| Full Article(HTML)(3559) \| Full Article (PDF)-868K(254) \| Full Article with Cover (PDF)-1222K(217) \| Full Article (XML)-154K(163) \| Audio-189K(26) \| Peer-Review Report-330K(137) \| Answering Reviewers-269K(154) \| Times Cited (10) \| Total Visits (5138) \| Open
16	Xin-Yang Zhang, Qin-Jun-Jie Chen, Feng Zhu, Min Li, Dan Shang. Dual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease?. World Journal of Gastroenterology 2024; 30(37): 4163-4167 doi: 10.3748/wjg.v30.i37.4163 Abstract(611) \| Core Tip(566) \| Full Article(HTML)(2216) \| Full Article (PDF)-388K(190) \| Full Article with Cover (PDF)-1010K(208) \| Full Article (XML)-65K(133) \| Audio-369K(20) \| Peer-Review Report-195K(120) \| Answering Reviewers-217K(128) \| Times Cited (1) \| Total Visits (2747) \| Open
17	Jordi Gratacós-Ginès, Edilmar Alvarado-Tapias, David Martí-Aguado, Hugo López-Pelayo, Ramón Bataller, Elisa Pose. Diagnosis and Management of Early Stages of ALD. Seminars in Liver Disease 2025; 45(02) doi: 10.1055/a-2541-2892
18	Manman Hou, Pin Song, Yue Chen, Xiaoran Yang, Pengnan Chen, Aizhi Cao, Yingdong Ni. Bile acids supplementation improves colonic mucosal barrier via alteration of bile acids metabolism and gut microbiota composition in goats with subacute ruminal acidosis (SARA). Ecotoxicology and Environmental Safety 2024; 287 doi: 10.1016/j.ecoenv.2024.117313
19	Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi, Issa S Al-Amri. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World Journal of Biological Chemistry 2025; 16(1): 104535 doi: 10.4331/wjbc.v16.i1.104535 Abstract(528) \| Core Tip(500) \| Full Article(HTML)(2294) \| Full Article (PDF)-1962K(330) \| Full Article with Cover (PDF)-2137K(247) \| Full Article (XML)-106K(146) \| Audio-528K(23) \| Peer-Review Report-316K(192) \| Answering Reviewers-330K(186) \| Times Cited (4) \| Total Visits (3874) \| Open
20	Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Ashok Iyaswamy. Peroxisome proliferator-activated receptor agonists: A new hope towards the management of alcoholic liver disease. World Journal of Gastroenterology 2024; 30(35): 3965-3971 doi: 10.3748/wjg.v30.i35.3965 Abstract(650) \| Core Tip(737) \| Full Article(HTML)(2590) \| Full Article (PDF)-394K(206) \| Full Article with Cover (PDF)-668K(181) \| Full Article (XML)-98K(143) \| Audio-1643K(17) \| Peer-Review Report-204K(174) \| Answering Reviewers-56K(141) \| Times Cited (3) \| Total Visits (3120) \| Open
21	Hong Wei, Li-Xuan Sang, Bing Chang. Elafibranor: A promising treatment for alcohol-associated liver disease?. World Journal of Gastroenterology 2024; 30(39): 4313-4317 doi: 10.3748/wjg.v30.i39.4313 Abstract(578) \| Core Tip(667) \| Full Article(HTML)(1894) \| Full Article (PDF)-383K(179) \| Full Article with Cover (PDF)-641K(184) \| Full Article (XML)-60K(139) \| Audio-991K(38) \| Peer-Review Report-219K(122) \| Answering Reviewers-102K(138) \| Times Cited (1) \| Total Visits (2396) \| Open
22	Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao. MetALD: new insights and unraveling therapeutic potential. Metabolism and Target Organ Damage 2025; 5(3) doi: 10.20517/mtod.2025.65
23	Xiaodan Li, Ying Liu, Chuyi Shen, Changzhuan Shao, Hongke Jiang. Association of dietary index for gut microbiota with frailty in middle-aged and older Americans: a cross-sectional study and mediation analysis. Frontiers in Nutrition 2025; 12 doi: 10.3389/fnut.2025.1615386
24	Tomoo Yamazaki, Edward E. Cable, Bernd Schnabl. Peroxisome proliferator–activated receptor delta and liver diseases. Hepatology Communications 2025; 9(2) doi: 10.1097/HC9.0000000000000646
25	Queralt Herms, Jordi Gratacós-Ginès, Elisa Pose. Alcohol-related liver disease. Gastroenterology Report 2025; 13 doi: 10.1093/gastro/goaf088